慧俪轻体 WTW 深 沪
等待开盘 10-04 09:30:00 美东时间
347.14
+1.360
+0.39%
华盛通- 最 高350.415
- 今 开346.37
- 成交量 65.36万股
- 最 低 344.67
- 昨 收 345.78
- 总市值 338.63亿
- 52周最高 350.415
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 283.41
- 委 比 -15.33%
- 总股本 9754.80万
- 历史最高 350.415
- 量 比 1.35
- 振 幅 1.66%
- 历史最低 -19.6505
- 每 手 1
- 风险率 19.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Commercial insurance market enters period of relative stability, while presenting opportunity for buyers, says Willis report
<p>Willis的最新报告指出，得益于过剩资本、技术进步及数据驱动的风险管理，商业保险市场正向有利于买方的方向转变。财产险及工伤补偿险费率下降，保险公司利用AI等技术提升服务，为企业提供更多元化的保障。然而，报告提醒，自然灾害、网络攻击等系统性风险可能破坏当前的市场稳定。保险公司需抓住当前机遇，同时为未来风险做好准备。</p>
10-03 17:55
美股大行评级 | 潜在涨幅162.68%！Ocular Therapeutix获JMP证券升目标价至29美元，维持"跑赢大市"评级
今日重点评级关注：JMP证券：维持Ocular Therapeutix"跑赢大市"评级，目标价从20美元升至29美元；汇丰银行：上调Banco BBVA Argentina评级至"买入"，目标价从21美元下调至17美元
10-02 15:08
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
Wells Fargo Maintains Overweight on Willis Towers Watson, Raises Price Target to $377
Wells Fargo analyst Elyse Greenspan maintains Willis Towers Watson (NASDAQ:WTW) with a Overweight and raises the price target from $358 to $377.
09-30 21:16
美股大行评级 | 潜在涨幅207.38%！GoldMining获HC Wainwright升目标价至3.75美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持GoldMining"买入"评级，目标价从3.25美元升至3.75美元；摩根士丹利：维持Crinetics Pharmaceuticals"超配"评级，目标价从65美元升至77美元
09-30 14:16
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
Raymond James Reiterates Strong Buy on Willis Towers Watson, Raises Price Target to $400
Raymond James analyst C. Gregory Peters reiterates Willis Towers Watson (NASDAQ:WTW) with a Strong Buy and raises the price target from $380 to $400.
09-23 00:37
Employers prepare for disruptive and transformative health plan changes, WTW survey finds
US employers are planning significant changes to their healthcare plans amid rising costs, with projected increases of 9.1% in 2026. Key drivers include high pharmacy costs, chronic conditions, and expensive claims. Employers are focusing on cost management through alternative plan designs, vendor efficiency, and clinical program expansions. Additionally, they are increasingly adopting AI to enhance healthcare delivery and management.
09-22 17:54
WTW Board Approves $1.5B Increase To Share Repurchase Authority
WTW (NASDAQ:WTW), a leading global advisory, broking and solutions company, announced that its Board of Directors approved an increase to the existing share repurchase authority in the amount of $1.5 billion. The $1.5
09-19 04:04
Future-ready power companies are seizing the advantages of a soft market, according to the Willis Power Market Review
Power companies are seeing relief as the market softens, with insurers competing and pricing easing in favor of buyers. Property damage and business interruption rates are dropping by mid to high double digits, while long-term agreements and no-claims bonuses return. Despite international liability market softening, climate change and decarbonisation impacts persist. Buyers turn to captives and alternative risk financing amid market volatility. T...
09-11 08:00
